Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...
Let's talk about menopause, AI, Alzheimer's and more health topics at South by Southwest, with some lab brains and nature ...
Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...
The Canadian Press on MSN13h
Today-History-Mar17
Today in History for March 17: ...
A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO ...
Curevo Vaccine raises $110M Series B for shingles vaccine trial extension, adds Moncef Slaoui as board chair and Moderna's ...